Consortium at a glance
A multilateral initiative to foster the clinical development of effective malaria vaccine candidates in Africa.
MIMVaC-Africa consortium is a large interdisciplinary consortium formed by malaria vaccine developpers from academia, industry and NGO, plus clinical trial experts.
The consortium constitutes in total of ten (10) partner institutions from the world, resolutely committed to the fight against malaria through the development of malaria vaccines. The MIMVaC-Africa officially started its activities on 31 March 2020 and is coordinated by the Groupe de Rechechre Action en Santé (GRAS) based in Burkina Faso.
MIMVaC-Africa is organized into seven (07) work packages which implement the activities.
The MIMVaC-Africa consortium is a large interdisciplinary consortium formed by leading vaccine developpers, clinical trial experts and malaria researchers.
The MIMVaC-Africa governance is multi-layered comprising the General assembly (GA), the Project Steering Committee (PSC) and an External Independent Scientific Advisory Group (EISAG).
Important milestones reached and publications (coming soon)
Thanks for taking a little times to follow our news through these articles.
“ None of us, acting alone, can achieve the success. ”
The consortium includes many of the foremost research groups in this field:
- Europe: Eberhard Karls Universität Tübingen (EKUT), Germany; The Chancellor, the Masters and the Scholars of the University of Oxford (UOXF), UK; European Vaccine Initiative (EVI), Germany; Leiden University Medical Center (LUMC), the Netherlands; and Luxembourg Institute of Health (LIH), Luxembourg;
- Asia: Osaka University, Japan.
- Africa : Groupe de Recherche Action en Santé (GRAS), Burkina Faso ; Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon ; Fundação Manhiça, Mozambique ; Ifakara Health Institute (IHI), Tanzania.